Post-transplant monitoring of renal allografts: are we there yet?
Transplantation has emerged as the therapy of choice for many patients with end organ failure. One of the major goals is to tailor immunosuppressive therapy to the individual needs of every patient to balance the risk for rejection and over-immunosuppression. This will require diagnostic tools that can detect harmful processes in the allograft early, and that can be measured repeatedly. This review will consider recent advances in our understanding of the molecular nature of these processes and how this information is being utilized to design novel diagnostic assays to non-invasively monitor allografts. Highlighted is the need for large-scale prospective multi-centre studies to validate assays that show early promise in single centre studies.
Nickerson
Peter
P
Manitoba Centre for Proteomics and Systems Biology, University of Manitoba, 799 John Buhler Research Centre, 715 McDermot Avenue, Winnipeg, Manitoba, Canada R3E 3P4. pnickerson@hsc.mb.ca
D015415:Biomarkers / Q000032:analysis; D006084:Graft Rejection / Q000276:immunology; D006085:Graft Survival / Q000276:immunology; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D007371:Interferon-gamma / Q000032:analysis; D007518:Isoantibodies / Q000032:analysis; D016030:Kidney Transplantation / Q000276:immunology*; D015166:Monitoring, Immunologic / Q000379:methods*; D014184:Transplantation, Homologous / Q000276:immunology*
D015415:Biomarkers; D006680:HLA Antigens; D007518:Isoantibodies; D007371:Interferon-gamma